Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Kiniksa Pharmaceuticals International (KNSA) Receivables - Other (2022)

Kiniksa Pharmaceuticals International filings provide 1 years of Receivables - Other readings, the most recent being $7.7 million for Q4 2022.

  • On a quarterly basis, Receivables - Other changed N/A to $7.7 million in Q4 2022 year-over-year; TTM through Dec 2022 was $7.7 million, a N/A change, with the full-year FY2022 number at $7.7 million, changed N/A from a year prior.
  • Receivables - Other hit $7.7 million in Q4 2022 for Kiniksa Pharmaceuticals International.
  • In the past five years, Receivables - Other ranged from a high of $7.7 million in Q4 2022 to a low of $7.7 million in Q4 2022.